Immunohistochemical expression of p53, bcl-2, mdm2 and waf1/p21 proteins in colorectal adenocarcinomas

Anticancer Research

Volumn 17, Issue 4 A, 1997, Pages 2571-2576

  Valassiadou, Kalliope E ^a   Stefanaki, Kalliope ^a   Tzardi, Maria ^a   Datseris, George ^a   Georgoulias, Vassilis ^a   Melissas, John ^a   Tsiftsis, Dimitris D ^a   Delides, George ^a   Kanavaros, Panagiotis ^a  

^a UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

Author keywords

Bcl 2; Colon adenocarcinomas; Immunohistochemistry; Mdm2; P21 Waf1; P53

Indexed keywords

PROTEIN BCL 2; PROTEIN P21; PROTEIN P53;

ARTICLE; COLON ADENOCARCINOMA; COLORECTAL CARCINOMA; CONTROLLED STUDY; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; LYMPH NODE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN LOCALIZATION;

ADENOCARCINOMA; ADENOMA; COLON; COLONIC NEOPLASMS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; HUMANS; IMMUNOENZYME TECHNIQUES; NUCLEAR PROTEINS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTO-ONCOGENE PROTEINS C-MDM2; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0030877712     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Jacks T, Weinberg RA: Cell-cycle control and its watchman. Nature 381: 643-644, 1996.
2. Lane DP: P53, guardian of the genome. Nature 358: 15-16, 1992.
3. Levine AJ, Momand J, Finley CA: The p53 tumor supressor gene. Nature 351: 453-456, 1991.
4. Nigro MJ, Baker SJ, Preisinger AC, Jessup JM, Hosterer R, Cleary K, Binger SH, Davidson N, Baylin S, Devilee P: Mutations in the p53 gene occur in diverse human tumour types. Nature 342: 705-708, 1989.
5. Hall PA, Lane DP: P53 in tumor pathology. J Pathol 172: 1-4, 1994.
6. Barak Y, Oren M: Enhanced binding of a 95 kd protein to p53 in cells undergoing p53 mediated growth arrest. EMBO J 11: 2115-2121, 1992.
7. Oliner JD, Pietenpol JA, Thiagalingam S, Gyuris J, Kinzler KW, Vogelstein B: Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature 362: 857-860, 1993.
8. Finlay CA: The mdm2 oncogene can overcome wild-type p53 suppression of transformed cell growth. Mol Cell Biol 13: 301-306, 1993.
9. Wu X, Bayle JH, Olson D, Levine AJ: The p53-mdm2 autoregulatory feedback loop. Genes & Dev 7: 1126-1132, 1993.
10. El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B: WAF1 a potential mediator of p53 tumour suppression. Cell 75: 817-825, 1993.
11. Miyashita T, Krajewski S, Krajewska M, Wang HG, Lin HK, Huffman B, Lieberman D, Reed JC: Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 6: 1796-1805, 1994.
12. Tsujimoto Y, Croce CM: Analysis of the structure transcripts and protein products of the bcl-2, the gene involved in human follicular lymphoma. Proc Natl Acad Sci USA 83: 5214-5218, 1986.
13. Nunez G, London L, Hockenbery D, Alexander M, McKearn JP: Deregulated bcl-2 expression selectively prolongs survival of growth factor-deprived hemopoietic cell lines. J Immunol 144: 3602-3610, 1990.
14. Miyashita T, Reed JC: Bc1-2 oncoprotein blocks chemotherapy induced apoptosis in a leukaemia cell line. Blood 81: 151-157,1993.
15. Hall AP, Meek D, Lane DP: P53 integrating the complexity. J Path 180: 1-5, 1996.
16. Kaklamanis L, Savage A, Mortensen N, Tsiotos P, Anagnostopoulou I, Biddolph S, Whitehouse R, Harris AL, Gatter KC: Early expression of bcl-2 protein in the adenoma-carcinoma sequence of colorectal neoplasia. J Pathol 179: 10-14, 1996.
17. Bronner MP, Culin C, Reed JC, Furth EE: The bcl-2 proto-oncogene and the gastrointestinal epithelial tumour progression model. Am J Pathol 146: 20-26, 1995.
18. Flohil CC, Janssen PA, Bosnian FT: Expression of bcl-2 protein in hyperplastic polyps, adenomas and carcinomas of the colon. J Pathol 178: 393-397, 1996.
19. Bosari S, Moneghini L, Graziani D, Lee AK, Murray JJ, Coggi G, Viale G: Bc1-2 oncoprotein in colorectal hyperplastic polyps, adenomas and adenocarcinomas. Human Pathol 26: 534-540, 1995.
20. Ofner D, Maier H, Riedmann B, Holzberger P, Nogler M, Totsch M, Bankfalvi A, Winde G, Bocker W, Schmid KW: Immunohistochemically detectable p53 and mdm-2 oncoprotein expression in colorectal carcinoma: prognostic significance. J Clin Pathol: Mol Pathol 48: M12-M16, 1995.
21. El-Deiry WS, Tokino T, Waldman T, Oliner JD, Velculescu VE, Burrell M, Hill DE, Healy E, Rees JL, Hamilton SR, Kinzler KW, Vogelstein B: Topological control of p21(Waf 1/Cip 1) expression in normal and neoplastic tissues. Cancer Res 55: 2910-2919, 1995.
22. Doglioni C, Pelosio P, Laurino L, Macri E, Meggiolaro E, Favretti F, Barbareschi M: P21/WAF1/CIP1 expression in normal mucosa and adenomas and adenocarcinomas of the colon: its relationship with differentiation. J Pathol 179: 248-253, 1996.
23. Kanavaros P, Kouvidou Ch, Ran DY, Tzardi M, Datseris G, Darivianaki K, Rondogianni D, Delides G: MDM-2 protein expression in nasopharyngeal carcinomas. Comparative study with p53 protein expression. J Clin Pathol: Mol Pathol 48: M322-M325, 1995.
24. Polyak K, Hamilton SR, Vogelstein B, Kanzler KW: Early alteration of cell-cycle regulated gene expression in colorectal neoplasia. Am J Pathol 149(2): 381-387, 1996.
25. Fearon ER, Vogelstein B: A genetic model for colorectal tumorigenesis. Cell 61: 759-767, 1990.
26. Reiferberger G, Liu L, Ichimura K, Schmidt EE, Collins VP. Amplification and overexpression of the mdm2 gene in a subset of human malignant gliomas without p53 mutations. Cancer Res 53: 2736-2739, 1993.
27. Baas IO, Mulder JWR, Offerhaus JA, Vogelstein B, Hamilton SR: An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms. J Pathol 172: 5-12, 1994.
28. Tzardi M, Kouvidou Ch, Panayotides I, Stefanaki K, Rontogianni D, Zois E, Koutsoumbi K, Eliopoulos G, Delides G, Kanavaros P: P53 protein expression in non-Hodgkin lymphomas (NHL). Comparative study with the wild-type p53-induced proteins mdm-2 and p21/waf1. J Clin Pathol: Mol Pathol 49: M1-M5, 1996.
29. Barbareschi M, Girlando S, Fellin G, Graffer U, Luciani L, Palma PD: Expression of mdm-2 and p53 protein in transitional cell carcinoma. Urol Res 22: 349-352, 1995.
30. McCann AH, Kirley A, Carney DN, Carbally N, Magee HM, Keating G, Detvan PA: Amplification of the mdm-2 gene in human breast cancer and its association with mdm-2 and p53 protein status. Br J Cancer 71: 981-985, 1995.
31. MarchettiA, Buttita F, Pellegrini S, Lori A, Bertacca G, Bevilacqua G: Absence of somatic mutations in the coding region of the WAF1/CIP1 gene in human breast, lung and ovarian carcinomas: a polymorphism at the codon 31. Int J Oncol 6: 187-189, 1995.
32. Li Y, Laurentpuig P, Salmon RJ, Thomas G, Hamelin R: Polymorphism and probable lack of mutation in the WAF1/CIP1 gene in colorectal cancer. Oncogene 10: 599-601, 1995.
33. Michieli P, Chedid M, Lin D, Pierce JH, Mercer WE, Givol D: Induction of WAF1/CIP1 by a p53 independent pathway. Cancer Res 54: 3391-3395, 1994.
34. Johnson M, Dimitrov D, Vojta PJ, et al: Evidence for a p53-independent pathway for upregulation of SDI1/CIP1/WAF1/p21 mRNA in human cells. Mol Carcinogenesis 11: 59-64, 1994.